About Us
Meet the team ready to see human and scientific potential realized
Strong team of experts in virology, plant-expression and medicine
We’re a team of future-minded individuals working to make the world a healthier place.
Striving to be at the forefront of global health efforts
We have a vision to become a world leader in plant-based biologics. Discover our story and how we are working to pave the way for a better tomorrow using our plant-based platform and innovative technologies. BAT-owned KBP is located in Owensboro, Ky., where it began operations in 2006. In January 2014, KBP was acquired by and became an independently operated, wholly-owned subsidiary of Reynolds American Inc. (RAI), owned by BAT.
2014
Produced an anti-Ebola monoclonal antibody cocktail ZMappTM in partnership with MappBio. Went from project start to clinical drug substance in under 6 weeks.
2014
Promising pre-clinical evidence showing the potential for our vaccine platform in pandemic Flu (Mallajosyula, Jyothi K., et al. 2014).
2015
Produced a monoclonal antibody intended to block sexual transmission of genital herpes and HIV for Phase I trials in collaboration with MappBio (MB66).
2020
Entered Phase I clinical trials with our investigational Quadrivalent Flu vaccine candidate.
2020
Entered Phase I clinical trials with our investigational COVID vaccine candidate.